.png)
Bio & Health Tech AI: Risks, Returns, and Roadmaps



This invitation-only event, co-hosted by the Institute for Experiential AI at Northeastern University and Grant Thornton, gathers leaders in AI, biotech, and venture capital for a focused discussion on current challenges and collaboration opportunities. The session will include case study highlights, group dialogue, and a networking reception to connect on potential partnerships.
This half-day session will feature:
- Case study highlights from EAI’s translational research and Grant Thornton’s work with AI in BioTech and HealthTech
- A candid roundtable discussion of pain points faced by VCs, CEOs, and technology leaders in AI adoption and scale
- Joint insights into how EAI and Grant Thornton are addressing barriers to implementation
- Optional tours of Northeastern’s AI-focused research labs
- A networking reception at the Faculty Club with faculty and research teams driving applied AI innovation
This event is designed to foster dialogue, surface shared challenges, and uncover opportunities for collaboration across sectors.
Keynote and Industry Speakers
Northeastern University Speakers
Agenda

Andrea De Souza, Qubit Pharmaceuticals, Chief Corporate Development Officer
The digital era of biology and healthcare has been poised to redefine healthcare through the transformative use of data, AI and now, quantum. Sustained innovation with data and AI has and will continue to drive insights and impact. With this short talk, we will weave in quantum AI as an additional catalyst for insights, innovation and impact as we highlight the risks, rewards and challenges required to ensure equitable and impactful advancements.
Andrea de Souza is the Chief Corporate Development Officer for Qubit Pharmaceuticals, an early-stage molecule discovery company focused on accelerating the use of AI, physics-based and Quantum AI at scale. As a tenured executive her career focus has included leadership roles with transformative impact at Amgen, the Broad Institute of Harvard and MIT, NVIDIA and Eli Lilly. She currently serves as an advisor to an AI fund and advises companies working at the intersection of life sciences, technology and new market development.





.png)







%20circ.png)
Attendee Testimonials





